CSF2 and rheumatoid arthritis: In the Rheumavax clinical trials (13) for rheumatoid arthritis, tDC generated in GM-CSF+IL-4 and the NF-κB inhibitor Bay 11-7082, exhibited lower CD40, and HLA-DR on a per cell basis (13).